Objective: A relationship between thyroid and non-organ-specific autoimmunity could be relevant for Graves’ orbitopathy (GO), which affects connective tissue. We investigated the association between GO and anti-nuclear antibodies (ANAs). Methods: Retrospective investigation was conducted in 265 patients with Graves’ disease (GD), 158 with and 107 without GO. Primary outcome was: prevalence of ANAs in GO vs no-GO. Secondary outcomes were: (1) relationship between ANAs and GO features; (2) prevalence of ANAs in GD compared with non-autoimmune hyperthyroidism [(78 patients with toxic nodular goiter (TNG)]; (3) distribution of ANA patterns. Results: ANAs were detected in 212 (80%) GD patients, but prevalence did not differ between GO (79.7%) and no-GO (80.3%). Higher ANA titers (1:160) were more common in GO (51.5 vs 38.3%), but only nearly significantly (OR 0.5; 95% CI: 0.3–1; P = 0.059). Proptosis was lower in ANA-positive patients (mean difference: − 1.4 mm; 95% CI from − 2.5 to − 0.3; P = 0.011), in whom nearly significantly lower CAS (Mann–Whitney U: 1.5; P = 0.077) and eyelid aperture (mean difference: − 0.9 mm; 95% CI from − 2 to 0; P = 0.062) were observed. Prevalence of ANAs in GD was lower than in TNG (80 vs 91%; OR 0.3; 95% CI: 0.1–0.9; P = 0.028), but nuclear speckled pattern was more frequent (OR 22.9; 95% CI 1.3–381.3; P = 0.028). Conclusions: Although ANAs are not more frequent in GO, they seem to exert a protective role on its severity and on development of GD. A switch of T cell population in ANA-positive patients, resulting in a different phenotype, may be responsible. Further studies are needed to investigate the mechanisms.

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy

Lanzolla G.;
2023-01-01

Abstract

Objective: A relationship between thyroid and non-organ-specific autoimmunity could be relevant for Graves’ orbitopathy (GO), which affects connective tissue. We investigated the association between GO and anti-nuclear antibodies (ANAs). Methods: Retrospective investigation was conducted in 265 patients with Graves’ disease (GD), 158 with and 107 without GO. Primary outcome was: prevalence of ANAs in GO vs no-GO. Secondary outcomes were: (1) relationship between ANAs and GO features; (2) prevalence of ANAs in GD compared with non-autoimmune hyperthyroidism [(78 patients with toxic nodular goiter (TNG)]; (3) distribution of ANA patterns. Results: ANAs were detected in 212 (80%) GD patients, but prevalence did not differ between GO (79.7%) and no-GO (80.3%). Higher ANA titers (1:160) were more common in GO (51.5 vs 38.3%), but only nearly significantly (OR 0.5; 95% CI: 0.3–1; P = 0.059). Proptosis was lower in ANA-positive patients (mean difference: − 1.4 mm; 95% CI from − 2.5 to − 0.3; P = 0.011), in whom nearly significantly lower CAS (Mann–Whitney U: 1.5; P = 0.077) and eyelid aperture (mean difference: − 0.9 mm; 95% CI from − 2 to 0; P = 0.062) were observed. Prevalence of ANAs in GD was lower than in TNG (80 vs 91%; OR 0.3; 95% CI: 0.1–0.9; P = 0.028), but nuclear speckled pattern was more frequent (OR 22.9; 95% CI 1.3–381.3; P = 0.028). Conclusions: Although ANAs are not more frequent in GO, they seem to exert a protective role on its severity and on development of GD. A switch of T cell population in ANA-positive patients, resulting in a different phenotype, may be responsible. Further studies are needed to investigate the mechanisms.
2023
Anti-nuclear autoantibodies; Graves’ disease; Graves’ ophthalmopathy; Graves’ orbitopathy; Non-organ-specific autoantibodies; Thyroid eye disease
File in questo prodotto:
File Dimensione Formato  
s40618-022-01906-3.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia: versione editoriale (VoR)
Dimensione 601.23 kB
Formato Adobe PDF
601.23 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/444451
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact